Patents Assigned to AbbVie Inc.
  • 5-substituted indazoles as kinase inhibitors
    Patent number: 9163007
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 20, 2015
    Assignee: AbbVie Inc.
    Inventors: Irini Akritopoulou-Zanze, Brian D. Wakefield, Helmut Mack, Sean C. Turner, Alan F. Gasiecki, Vijaya J. Gracias, Kathy A. Sarris, Douglas M. Kalvin, Melissa J. Michmerhuizen, Qi Shuai, Jyoti R. Patel, Margaretha H. M. Bakker, Nicole Teusch, Eric F. Johnson, Peter J. Kovar, Stevan W. Djuric, Andrew J. Long, Anil Vasudevan, Dawn M. George, Lu Wang, Biqin Li, Nigel S. Moore, Adrian D. Hobson, Keith W. Woods, Julie M. Miyashiro, Steven L. Swann, Jr., Thomas D. Penning
  • TRPV3 modulators
    Patent number: 9156788
    Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 13, 2015
    Assignee: AbbVie Inc.
    Inventors: Erol K. Bayburt, Bruce Clapham, Phil B. Cox, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Eric A. Voight
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9156856
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: October 13, 2015
    Assignee: AbbVie Inc.
    Inventors: Aaron R. Kunzer, Steven W. Elmore, Laura A. Hexamer, Cheol-Min Park, Andrew J. Souers, Gerard M Sullivan, Gary T. Wang, Xilu Wang, Michael D. Wendt
  • Methods for Treating HCV
    Publication number: 20150283198
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 1, 2015
    Publication date: October 8, 2015
    Applicant: AbbVie Inc
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang
  • Methods for Treating HCV
    Publication number: 20150283199
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 1, 2015
    Publication date: October 8, 2015
    Applicant: ABBVIE INC.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang
  • Cell culture methods to reduce acidic species
    Patent number: 9150645
    Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 6, 2015
    Assignee: AbbVie, Inc.
    Inventors: Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Christopher Chumsae
  • Heterocyclic nuclear hormone receptor modulators
    Patent number: 9150592
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 6, 2015
    Assignee: AbbVie Inc.
    Inventors: Kevin P. Cusack, Thomas D. Gordon, Michael Z. Hoemann, David C. Ihle, Bin Li, Gloria Y. Lo Schiavo, Gagandeep K. Somal, Michael Friedman, Martin E. Hayes, Wouter Iwema Bakker
  • Carboxamide compounds and their use as calpain inhibitors V
    Patent number: 9150545
    Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 6, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Andreas Kling, Katja Jantos, Helmut Mack, Achim Möller, Wilfried Hornberger, Gisela Backfisch, Yanbin Lao, Marjoleen Nijsen
  • CRYSTALLINE FORM OF A DRUG
    Publication number: 20150266860
    Abstract: Atrasentan Hydrochloride Crystalline Form 3, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Application
    Filed: June 2, 2015
    Publication date: September 24, 2015
    Applicant: AbbVie Inc.
    Inventor: Geoff G.Z. ZHANG
  • Radiolabeled PDE10A ligands
    Patent number: 9138494
    Abstract: Compounds of formula (I) are disclosed Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as PDE10A positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compound of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 22, 2015
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Lawrence A. Black, Berthold Behl, Jill Wetter
  • Anti-infective agents and uses thereof
    Patent number: 9139536
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 22, 2015
    Assignee: AbbVie Inc.
    Inventors: Charles A. Flentge, Douglas K. Hutchinson, David A. Betebenner, David A. DeGoey, Pamela L. Donner, Warren M. Kati, Allan C. Krueger, Dachun Liu, Yaya Liu, Kenton L. Longenecker, Clarence J. Maring, Christopher E. Motter, John K. Pratt, John T. Randolph, Todd W. Rockway, Kent D. Stewart, Rolf Wagner, Shuang Chen, Yi Gao, Xiaochun Lou, Geoff G. Z. Zhang
  • Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
    Patent number: 9133145
    Abstract: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: September 15, 2015
    Assignee: AbbVie Inc.
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven X. Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, James T. Link, Yixian Chen, Hwan-soo Jae, Jyoti R. Patel, Marina A. Pliushchev, Jeffrey J. Rohde, Qi Shuai, Bryan K. Sorensen, Martin Winn, Dariusz Wodka, Hong Yong
  • Therapeutic DLL4 binding proteins
    Patent number: 9132190
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: September 15, 2015
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Benzodiazepine and pyridodiazepine derivatives
    Patent number: 9133206
    Abstract: The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R1, R2, R3, R4, X1, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: September 15, 2015
    Assignee: AbbVie Inc.
    Inventors: William H. Bunnelle, Marc Scanio, Jason T. Brewer, Ying Wang, Irini Akritopoulou-Zanze
  • CHARACTERIZATION AND/OR DETECTION OF STRUCTURAL CHARACTERISTICS ASSOCIATED WITH SYRINGES AND/OR AUTOMATIC INJECTION DEVICES BASED ON ACOUSTICS
    Publication number: 20150253289
    Abstract: Exemplary embodiments relate to characterizing and/or detecting structural characteristics of syringes (e.g., bare syringes or syringes included in automatic injection devices) using acoustic vibrations. Exemplary embodiments can position a transducer proximate to a syringe so that the transducer vibrates at one or more frequencies and a response of the syringe to the vibrations can be received via the receiver. The response of syringe can be processed to determine a structural characteristic of the syringe.
    Type: Application
    Filed: October 11, 2013
    Publication date: September 10, 2015
    Applicant: AbbVie Inc.
    Inventors: Jose L. Bardina, Jovo Dragicevic, Jose M. Rodriguez, Lewis H. Sita
  • Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
    Patent number: 9125913
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 8, 2015
    Assignee: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • Dual specific binding proteins directed against IL-13 and IL-17
    Patent number: 9120870
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: September 1, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Tariq Ghayur, Carrie L. Goodreau
  • Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof
    Patent number: 9115151
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: August 25, 2015
    Assignee: AbbVie Inc.
    Inventors: Dawn M. George, Maria A. Argiriadi, Martine Barth, Dominique Bonafoux, Eric C. Breinlinger, Linlin Dai, Jeremy Edmunds, Michael M. Friedman, Fabrice Guillier, Adrian D. Hobson, Dominique Potin, Didier Thomas, Jianfei Wang, Wentao Wu, Yang Zhang
  • Therapeutic DLL4 binding proteins
    Patent number: 9115195
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: August 25, 2015
    Assignee: ABBVIE INC.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li
  • Dual variable domain immunoglobulins and uses thereof
    Patent number: 9109026
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: August 18, 2015
    Assignee: ABBVIE, INC.
    Inventors: Tariq Ghayur, Alfred Hahn, Bernhard Mueller